Metastatic Malignant Neoplasm to the Leptomeninges Recruiting Phase 2 Trials for Nimotuzumab (DB06192)

Also known as: Leptomeningeal Metastasis / Neoplastic Meningitis / Leptomeningeal Metastases / Metastatic Malignant Neoplasm in the Leptomeninges / Leptomeningeal Disease (LMD) / Leptomeningeal Disease / Lymphomatous meningitis / Leptomeningeal Carcinomatosis / Metastatic malignant neoplasm to leptomeninges (disorder) / Lymphomatous meningitis (disorder) / Malignant meningitis (disorder) / Leptomeningeal Neoplasms / Meningeal dissemination / Metastases to meninges / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0057483 (Metastatic Malignant Neoplasm to the Leptomeninges)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04833205Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung CancerTreatment